Sartorius Stedim Biotech S.A. (OTCPK:SDMHF) Q3 2024 Earnings Conference Call October 17, 2024 7:00 AM ET
Company Participants
Joachim Kreuzburg – Chairman
René Fáber – Chief Executive Officer
Florian Funck – Chief Financial Officer
Conference Call Participants
Zain Ebrahim – JPMorgan
Charles Pitman-King – Barclays
Charles Weston – RBC Capital Markets
Charlie Haywood – Bank of America
Oliver Metzger – Oddo BHF
Dylan Van Haaften – Stifel
Falko Friedrichs – Deutsche Bank
James Vane-Tempest – Jefferies International Limited
Thomas DeBourcy – Nephron Research
Paul Knight – KeyBanc Capital Markets
Delphine Le Louet – Bernstein
Ed Ridley-Day – Redburn Atlantic
Oliver Burrow – Goldman Sachs
Harry Sephton – UBS
Operator
Ladies and gentlemen, welcome to the Sartorius and Sartorius Stedim Biotech Conference Call on the Nine Months 2024 Results. I am Surgeon, the Chorus Call operator. I would like to remind you that all participants will be in a listen-only mode and the conference is being recorded. The presentation will be followed by a Q&A session. [Operator Instructions] The conference must not be recorded for publication or broadcast.
At this time, it’s my pleasure to hand over to Dr. Joachim Kreuzburg. Please go ahead, sir.
Joachim Kreuzburg
Thank you, very much. Welcome everyone and good day and a pleasure to walk you through our results for the first nine months of 2024. As always we will do this together. That means it’s myself and Florian Funck, CFO of the Sartorius Group as well as René Fáber, CEO of Sartorius Stedim Biotech and we will start with the results of Sartorius AG or the Sartorius Group and then thereafter we will walk you through the additional information on Sartorius Sartorius Stedim Biotech.
So let me start with highlighting the key results of the first nine months of 2024 and I think the
